PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Sig Transduct Target Ther 5, 38 (2020). https://doi.org/10.1038/s
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Sig Transduct Target Ther 5, 38 (2020). https://doi.org/10.1038/s
复制标题
DOI：
10.1038/s41392-020-0144-8
复制
发表时间：
2020
影响因子：
39.3
通讯作者：
He Ren
中科院分区：
文献类型：
--
作者：
Xiuchao Wang;Xin Li;Hailing Jiang;Chungen Lan;Shengyu Yang;Han Wang;Yanhui Yang;Caiman Tian;Zanmei Xu;Jiangyan Zhang;Jihui Hao;He Ren
